[go: up one dir, main page]

CL2008000539A1 - Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epo - Google Patents

Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epo

Info

Publication number
CL2008000539A1
CL2008000539A1 CL200800539A CL2008000539A CL2008000539A1 CL 2008000539 A1 CL2008000539 A1 CL 2008000539A1 CL 200800539 A CL200800539 A CL 200800539A CL 2008000539 A CL2008000539 A CL 2008000539A CL 2008000539 A1 CL2008000539 A1 CL 2008000539A1
Authority
CL
Chile
Prior art keywords
agonist
heteroycle
espiro
glucocorticoid
epo
Prior art date
Application number
CL200800539A
Other languages
English (en)
Inventor
Tomas Hansson Johan M Eriksson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2008000539A1 publication Critical patent/CL2008000539A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200800539A 2007-02-23 2008-02-22 Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epo CL2008000539A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89124407P 2007-02-23 2007-02-23

Publications (1)

Publication Number Publication Date
CL2008000539A1 true CL2008000539A1 (es) 2008-10-10

Family

ID=39710315

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800539A CL2008000539A1 (es) 2007-02-23 2008-02-22 Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epo

Country Status (8)

Country Link
US (1) US20110124613A1 (es)
EP (1) EP2120935A4 (es)
AR (1) AR065453A1 (es)
CL (1) CL2008000539A1 (es)
PE (1) PE20090491A1 (es)
TW (1) TW200848035A (es)
UY (1) UY30935A1 (es)
WO (1) WO2008103126A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009543860A (ja) * 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用
UY32521A (es) * 2009-04-03 2010-10-29 Astrazeneca Ab Combinación para emplear en el tratamiento de enfermedades respiratorias
WO2012163848A1 (en) 2011-05-27 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of crohn's disease
WO2013060865A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100940A1 (en) * 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
GB201918692D0 (en) 2019-12-18 2020-01-29 Cambridge Entpr Ltd Treatment and prognosis of pancreatic cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
SE0202133D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
SE0303090D0 (sv) * 2003-11-20 2003-11-20 Astrazeneca Ab Novel compounds
SE0303280D0 (sv) * 2003-12-05 2003-12-05 Astrazeneca Ab Novel compounds
SE0303541D0 (sv) * 2003-12-22 2003-12-22 Astrazeneca Ab New compounds
JP2009506029A (ja) * 2005-08-26 2009-02-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患、特に慢性閉塞性肺疾患(copd)および喘息の処置に使用し得る化合物の組み合わせ
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
JP2009543860A (ja) * 2006-07-19 2009-12-10 アストラゼネカ・アクチエボラーグ 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用

Also Published As

Publication number Publication date
PE20090491A1 (es) 2009-05-31
EP2120935A1 (en) 2009-11-25
EP2120935A4 (en) 2011-06-22
AR065453A1 (es) 2009-06-10
US20110124613A1 (en) 2011-05-26
UY30935A1 (es) 2008-09-30
WO2008103126A1 (en) 2008-08-28
TW200848035A (en) 2008-12-16

Similar Documents

Publication Publication Date Title
CL2007003755A1 (es) Compuestos derivados de indol; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de afecciones o trastornos mediados por receptores s1p1 tales como enfermedades autoinmunitarias, asma, neuropatias, artritis, diabe
WO2010141768A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
WO2012037410A3 (en) Estrogen receptor modulators and uses thereof
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
TWI562994B (en) Fgf receptor (fgfr) agonist dimeric compounds, process for the preparation thereof and therapeutic use thereof
WO2011041462A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
IL233325A0 (en) Dimeric compounds as an agonist for the fgfr (fgf) receptor, a process for their preparation and their therapeutic use
CL2008000539A1 (es) Producto farmaceutico que comprende un compuesto derivado de heterocilo espiro condensado, un agonista del receptor de glucocorticoides y opcionalmente un agonista beta2; y su uso para el tratamiento de enfermedades de las vias aereas, tales como epo
CL2007001887A1 (es) Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
CL2007002121A1 (es) Compuestos derivados de pirazoles, activadores de glucoquinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que comprende dichos compuestos; y uso para el tratamiento de enfermedades y/o trastornos metabolicos, tal como diab
CL2007002099A1 (es) Compuestos derivados de 3h-espiro(1-benzofuran-2,4'-piperidina); proceso de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento de enfermedades respiratorias, tales como epoc y asma.
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
WO2014066799A3 (en) Modulators of resistant androgen receptor
WO2010085820A3 (en) Tricyclic compounds as antagonists of prostaglandin d2 receptors
ZA201008886B (en) Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
CL2007002643A1 (es) Compuestos derivados de 5-fenil-nicotinamida, moduladores del receptor de cb1; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de trastornos de la nutricion, diabetes tipo ii y dependencia de sustan
CL2008000289A1 (es) Compuestos derivados de pirano[2,3-b]piridina, moduladores del receptor cannabinoide-1; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como psicosis, enfermedad de alzheimer, migrana, enfermedad de parkinson, asma y obesida
CL2011000184A1 (es) Compuestos derivados de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno; agonista de receptores de melatonina; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a los compuestos; y su uso de los compuestos en la preparacion de medicamentos.
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
CL2007003503A1 (es) Compuestos derivados de indol-2-il-carbonil-piperidina-benzoimidazolona y de indol-2-il-carbonil-piperidina-benzoxazolona, antagonistas del receptor de la v1a; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de dismenorrea
CL2008000540A1 (es) Producto farmaceutico que comprende un compuesto derivado de heterociclo sustituido o herterociclo espiro condensado y un antagonista muscarinico; y su uso para el tratamiento de enfermedades de las vias aereas tales como epoc o asma.
CR20110045A (es) Derivados de estratrienos que comprenden bioisosteros heterociclicos para el anillo fenëlico a